Sign up to save your podcasts
Or
Share NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
View all episodes
By BiotechTV
4.3
66 ratings
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
More shows like BiotechTV - News
View all
Motley Fool Money
3,222 Listeners
Odd Lots
1,910 Listeners
The Long Run with Luke Timmerman
124 Listeners
The Readout Loud
324 Listeners
Biotech 2050 Podcast
61 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
9,957 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Business Breakdowns
353 Listeners
Biotech Hangout
19 Listeners
Bloomberg Tech
60 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
512 Listeners
Uncapped with Jack Altman
41 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners
Cheeky Pint
48 Listeners